HENLIUS (02696) Amends Licensing Agreement for HANSIZHUANG® with Abbott and KGBio

Stock News02-24 17:00

HENLIUS (02696) announced that on February 24, 2026, following friendly negotiations, the company entered into an amendment and partial termination agreement with KGBio. This agreement terminates the exclusive licensing rights for the licensed product in regions outside of Indonesia under the original KGBio license agreement. On the same day, the company entered into an amendment to the license agreement with Abbott, revising certain terms related to the licensed territories and milestone payments for the licensed product under the original Abbott agreement. The revisions are intended to further expand the licensed territories for the product to include the regions terminated with KGBio and other specified countries or areas. After friendly discussions, HENLIUS and KGBio have ended their commercialization collaboration for the licensed product in the terminated regions. The exclusive commercialization rights for the product in the newly added territories have been granted to Abbott. Previously, HENLIUS has established a strong cooperative relationship with Abbott for the commercialization of several products in numerous regions globally. This expansion of the collaboration with Abbott for the licensed product in the new territories is expected to better facilitate the product's expansion into overseas markets and enhance its accessibility and recognition in the international market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175106036?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175106036","market":"nz","top_or_hot":-1,"title":"HENLIUS (02696) Amends Licensing Agreement for HANSIZHUANG® with Abbott and KGBio","media":"Stock News","content":"<p>HENLIUS (02696) announced that on February 24, 2026, following friendly negotiations, the company entered into an amendment and partial termination agreement with KGBio. This agreement terminates the exclusive licensing rights for the licensed product in regions outside of Indonesia under the original KGBio license agreement. On the same day, the company entered into an amendment to the license agreement with Abbott, revising certain terms related to the licensed territories and milestone payments for the licensed product under the original Abbott agreement. The revisions are intended to further expand the licensed territories for the product to include the regions terminated with KGBio and other specified countries or areas. After friendly discussions, HENLIUS and KGBio have ended their commercialization collaboration for the licensed product in the terminated regions. The exclusive commercialization rights for the product in the newly added territories have been granted to Abbott. Previously, HENLIUS has established a strong cooperative relationship with Abbott for the commercialization of several products in numerous regions globally. This expansion of the collaboration with Abbott for the licensed product in the new territories is expected to better facilitate the product's expansion into overseas markets and enhance its accessibility and recognition in the international market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS (02696) Amends Licensing Agreement for HANSIZHUANG® with Abbott and KGBio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS (02696) Amends Licensing Agreement for HANSIZHUANG® with Abbott and KGBio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-24 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS (02696) announced that on February 24, 2026, following friendly negotiations, the company entered into an amendment and partial termination agreement with KGBio. This agreement terminates the exclusive licensing rights for the licensed product in regions outside of Indonesia under the original KGBio license agreement. On the same day, the company entered into an amendment to the license agreement with Abbott, revising certain terms related to the licensed territories and milestone payments for the licensed product under the original Abbott agreement. The revisions are intended to further expand the licensed territories for the product to include the regions terminated with KGBio and other specified countries or areas. After friendly discussions, HENLIUS and KGBio have ended their commercialization collaboration for the licensed product in the terminated regions. The exclusive commercialization rights for the product in the newly added territories have been granted to Abbott. Previously, HENLIUS has established a strong cooperative relationship with Abbott for the commercialization of several products in numerous regions globally. This expansion of the collaboration with Abbott for the licensed product in the new territories is expected to better facilitate the product's expansion into overseas markets and enhance its accessibility and recognition in the international market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1175106036","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175106036","pubTimestamp":1771923627,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) announced that on February 24, 2026, following friendly negotiations, the company entered into an amendment and partial termination agreement with KGBio. This agreement terminates the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","02696":"复宏汉霖","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC"},"translate_title":"复宏汉霖(02696)修订汉斯庄许可协议®与雅培和KGBio","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"HENLIUS (02696) announced that on February 24, 2026, following friendly negotiations, the company entered into an amendment and partial termination agreement with KGBio. This agreement terminates the exclusive licensing rights for the licensed product in regions outside of Indonesia under the original KGBio license agreement. On the same day, the company entered into an amendment to the license agreement with Abbott, revising certain terms related to the licensed territories and milestone payments for the licensed product under the original Abbott agreement. The revisions are intended to further expand the licensed territories for the product to include the regions terminated with KGBio and other specified countries or areas. After friendly discussions, HENLIUS and KGBio have ended their commercialization collaboration for the licensed product in the terminated regions. The exclusive commercialization rights for the product in the newly added territories have been granted to Abbott. Previously, HENLIUS has established a strong cooperative relationship with Abbott for the commercialization of several products in numerous regions globally. This expansion of the collaboration with Abbott for the licensed product in the new territories is expected to better facilitate the product's expansion into overseas markets and enhance its accessibility and recognition in the international market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175106036","isCrawlerRequest":true}